1.藍佩琪：探討靈芝免疫調節功能蛋白抑制乳癌侵襲轉移的能力，台灣，中山醫學大學 生化所碩士論文，2010。2.Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, Bliss J, Johnson L, Earl H, Poole C, Hiller L, Dunn J, Hopwood P, Barrett-Lee P, Ellis P, Cameron D, Harris AL, Gray AM, Sculpher MJ. (2011) The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European journal of cancer. 11:p.1~14.
3.Zhao X, Sun X, Gao F, Luo J, Sun Z. (2011) Effects of ulinastatin and docataxel on breast tumor growth and expression of IL-6, IL-8, and TNF-a. Journal of Experimental Clinical Cancer Research. 30:p.22.
4.Ko JL, Hsu CI, Lin RH, Kao CL, Lin JY. (1995) A new fungal immunomodulatory protein, FIP-fve isolated from the edible mushroom, Flammulina velutipes and its complete amino acid sequence. European journal of biochemistry. 228:p.244-249.
5.Kino K, Yamashita A, Yamaoka K, Watanabe J, Tanaka S, KO K, Shimizu K, Tsunoo H. (1989) Isolation and characterization of a new immunomodulatory protein, ling zhi-8 (LZ-8), from Ganoderma lucidium. The Jouranal of Biological Chemistry. 264:p.472–478.
6.Lin YL, Liang YC, Tseng YS, Huang HY, Chou SY, Hseu RS, Huang CT, Chiang BL. (2009) An immunomodulatory protein, Ling Zhi-8,induced activation and maturation of human monocyte-derived dendritic cells by the NF-κB and MAPK pathways. Journal of Leukocyte Biology. 86:p.877-889.
7.Lin CH, Sheu GT, Lin YW, Yeh CS, Huang YH, Lai YC, Chang JG, Ko JL. (2010) A new immunomodulatory protein from Ganoderma microsporum inhibits epidermal growth factor mediated migration and invasion in A549 lung cancer cells. Process Biochemistry. 45:p. 1537–1542.
8.Lin WH, Hung CH, Hsu CI, Lin JY. (1997) Dimerization of the N-terminal amphipathic alpha-helix domain of the fungal (Fip-gts) defined by a yeast two-hybrid system and site-directed mutagenesis. The Jouranal of Biological Chemistry. 272:p.20044-20048.
9.Lin CH, Hsiao YM, Ou CC, Lin YW, Chiu YL, Lue KH, Chang JG, Ko JL. (2010) GMI, a Ganoderma Immunomodulatory Protein, Down-regulates Tumor Necrosis Factor r-Induced Expression of Matrix Metalloproteinase 9 via NF-KB Pathway in Human Alveolar Epithelial A549 Cells. Journal of Agricultural and Food Chemisry. 58:p.12014–12021.
10.Jiang J, Slivova V, Harvey K, Valachovicova T, Sliva D. (2004) Ganoderma lucidum suppresses growth of breast cancer cells through the inhibition of Akt/NF-κB signaling. Nutrition and Cancer. 49:p.209-216.
11.Yue GG, Fung KP, Tse GM, Leung PC, Lau CB. (2006) Comparative studies of various ganoderma species and their different parts with regard to their antitumor and immunomodulating activities in vitro. Journal of alternative and complementary medicine. 12:p.777–789.
12.Vermeulen K, Bockstaele DR, Berneman ZN. (2003) The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Proliferation. 36:p.131–149.
13.Morgan DO. (1995) Principles of CDK regulation. Nature 374:p.131.
14.Mudrak I, Ogris E, Rotheneder H, Wintersberger E. (1994) Coordinated trans-activation of DNA synthesis and precursor producing enzymes by polyomavirus large T antigen through interaction with the retinoblastoma protein. Molecular and Cellular Biology. 14:p.1886-1892.
15.Arroyo M and Raychaudhuri P. (1992) Retinoblastoma-repression of E2F dependent transcription depends on the ability of the retinoblastoma protein to interact with E2F and is abrogated by the adenovirus E1A oncoprotein. Nucleic Acids Research. 20:p.5947-5954.
16.Kimberly AS. (1998) The Cell Cycle:A Review. Veterinary Pathology. 35:p.461-478.
17.Tamura T, Ishihara M, Lamphier MS, Tanaka N, Oishi I, Aizawa S, Matsuyama T, Mak TW, Taki S, Taniguchi T. (1997) DNA damage-induced apoptosis and Ice gene induction in mitogenically activated T lymphocytes require IRF-1. Leukemia. 3:p.439-440.
18.Yin XM.(2000) Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Research. 10:p.161-167.
19.Degterev A, Boyce M, Yuan J. (2003) A decade of caspases. Oncogene 22:p.8543–8567.
20.Nagata S. (2000) Apoptotic DNA fragmentation. Experimental Cell Research. 256:p.12–18.
21.Hengartner MO. (2000) The biochemistry of apoptosis. Nature 407:p.770–776.
22.Lodish H, Berk A, Kaiser CA, Krieger M, Matthew P, Bretscher SA, Ploegh H, Matsudaira P. (2007) Molecular Cell Biology. 6:p.936.
23.Ashkenazi A and Dixit VM. (1999) Apoptosis control by death and decoy receptors. Current Opinion Cell Biology. 11:p.255–260.
24.Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annual Reviews Immunology. 17:p.331–367.
25.Ashkenazi A and Dixit VM. (1998) Death receptors: signaling and modulation. Science. 281:p.1305–1308.
26.Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J, Krammer PH, Walczak H. (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 12:p.599–609.
27.Hengartner MO. (2000) The biochemistry of apoptosis. Nature 407:p.770-776.
28.Mayer B, Oberbauer R. (2003) Mitochondrial regulation of apoptosis. News in physiological sciences. 18:p.89-94.
29.Korsmeyer SJ, Yin XM, Oltvai ZN, Veis-Novack DJ, Linette GP. (1995) Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Biochimica et Biophysica Acta 1271:p.63-66.
30.Henry-Mowatt J, Dive C, Martinou JC, James D. (2004) Role of mitochondrial membrane permeabilization in apoptosis and cancer. Oncogene. 23:p.2850–2860.
31.van Loo G, Saelens X, van Gurp M, Macfarlane M, Martin SJ, Vandenabeele P. (2002) The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differentiation. 9:p.1031–42.
32.Bhardwaj A, Aggarwal BB. (2003) Receptor-mediated choreography of choreography of life and death. Journal of Clinical Immunology 23:p.317-327.
33.Jack TZ, Scott WL. (2011) Tumor Suppressive Functions of p53. Cold Spring Harbor Perspectives in Biology. 1:p.1~12.
34.Yee KS, Vousden KH. (2005) Complicating the complexity of p53. Carcinogenesis. 26:p.1317–1322.
35.Greenblatt MS, Bennett WP, Hollstein M, Harris CC. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Research. 54:p.4855-4878.
36.Vousden KH and Prives C. (2009) Blinded by the light: the growing complexity of p53. Cell. 137:p.413-431.
37.Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. (2005) PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science. 309:p.1732-1735.
38.Brady CA and Attardi LD. (2010) p53 at a glance. Journal of Cell Science. 123:p.2527-2532.
39.Miller LJ, Kurtzman SH, Anderson K,Wang Y, Stankus M, Renna M,et al. (2000) Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Investigation. 18:p.293–302.
40.Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, et al. (2003) The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumour progression. International journal of oncology. 23:p.269–84.
41.Singer CF, Kronsteiner N, Hudelist G, Marton E, Walter I, Kubista M, et al. (2003) Interleukin 1 system and sex steroid receptor expression in human breast cancer: interleukin 1 alpha protein secretion is correlated with malignant phenotype. Clinical Cancer Research. 9:p.4877–4883.
42.Liu L and Gudas LJ. (2002) Retinoic acid induces expression of the interleukin-1beta gene in cultured normal human mammary epithelial cells and in human breast carcinoma lines. Journal of cellular physiology. 193:p.244–252.
43.Liu Y, Li PK, Li C, Lin J. (2010) Inhibition of STAT3 Signaling Blocks the Anti-apoptotic Activity of IL-6 in Human Liver Cancer Cells. The Jouranal of Biological Chemistry. 285:p.27429-27439.
44.Hodge DR, Hurt EM, Farrar WL. (2005) The role of IL-6 and STAT3 in inflammation and cancer. European Journal of Cancer. 41:p.2502–2512.
45.Hirano T, Akira S, Taga T, Kishimoto T. (1990) Biological and clinical aspects of interleukin 6. Immunol Today. 11:p.443–449.
46.Kishimoto T. (1989) The biology of interleukin-6. Blood 74:p.1–10.
47.Kishimoto T. (2005) Interleukin-6: from basic science to medicine—40 years in immunology. Annual Review Immunology. 23:p.1–21.
48.Bharti AC, Donato N, Aggarwal BB. (2003) Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. The Journal of immunology. 171:p.3863–3871.
49.Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, TaffurelliM, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafe M. (2007) IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. The Journal of Clinical Investigation. 117:p.3988–4002.
50.Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis W D, Bornmann W, Veach D, Clarkson B, Bromberg JF. (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. The Journal of Clinical Investigation. 117:p.3846–3856.
51.Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. (2000) Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. The Prostate. 42:p.239–242.
52.Wei LH, Kuo ML, Chen CA, Chou CH, Cheng WF, Chang MC, Su JL, Hsieh CY. (2001) The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene. 20:p.5799–5809.
53.Lin MT, Juan CY, Chang KJ, Chen WJ and Kuo ML. (2001) IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1.Carcinogenesis. 22:p.1947–1953.
54.Leu CM, Wong FH, Chang C, Huang SF and Hu CP. (2003) Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene. 22:p.7809–7818.
55.Honma S, Shimodaira K, Shimizu Y, Tsuchiya N, Saito H, Yanaihara T, et al. (2002) The influence of inflammatory cytokines on estrogenproduction and cell proliferation in human breast cancer cells. Endocrine journal. 49:p.371–377.
56.Kurebayashi J. (2000) Regulation of interleukin-6 secretion from breast ancer cells and its clinical implications. Breast Cancer. 7:p.124–129.
57.Knupfer H, Schmidt R, Stanitz D, Brauckhoff M, Schonfelder M, Preiss R. (2004) CYP2C and IL-6 expression in breast cancer. Breast. 13:p.28–34.
58.Taub R. (2003) Hepatoprotection via the IL-6/Stat3 pathway. The Jounal Clinical Investigation. 112:p.978–980.
59.Kovacs E. (2001) Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed Pharmacother. 55:p.391–396.
60.Trikha M, Corringham R, Klein B, Rossi JF. (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clinical Cancer Research. 9:p.4653–4665.
61.Banks RE, Forbes MA, Patel PM, Storr M, Hallam S, Clarke D, et al. (2000) Subcutaneous administration of recombinant glycosylated interleukin-6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects. Cytokine. 12:p.388–396.
62.Purohit A, Newman SP, Reed MJ. (2002) The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Research. 4:p.65–69.
63.Mettler L, Salmassi A, Heyer M, Schmutzier A, Schollmeyer T, Jonat W. (2004) Perioperative levels of interleukin-1beta and interleukin-6 in women with breast cancer. Clinical and experimental obstetrics & gynecology. 31:p.20–22.
64.Zhang GJ, Adachi I. (1999) Serum interleukin-6 levels correlate to tumour progression and prognosis in metastatic breast carcinoma. Anticancer Research. 19:p.1427–1432.
65.Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. (2003) Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. British journal of cancer. 88:p.1721–17216.
66.Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdogan M, et al. (2004) Tumour necrosis factor- alpha, interleukin-6, and fasting seruminsulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine. 7:p.58–65.
67.Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, et al. (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. International journal of cancer. 103:p.642–646.
68.Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, et al. (2000) An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer. Oncology. 59:p.166–173.
69.Mitsuyama K, Sata M, Stefan RJ. (2006) Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine & Growth Factor Reviews. 17:p.451–461.
70.Hirano T, Ishihara K, Hibi M. (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 19:p.2548–2556.
71.Hirano T, Nakajima K, Hibi M. (1997) Signaling mechanismsthrough gp130: a model of the cytokine system. Cytokine Growth Factor Reviews. 8:p.241–252.
72.Mansson E, Stridh H, Albertionia F. (2002) Resistance to mitochondrial- and Fas-mediated apoptosis in human leukemic cells with acquired resistance to 9-β-D-arabinofuranosylguanosine. Biochemical and Biophysical Research Communications. 298:p.338–344.
73.Kothapalli D, Zhao L, Hawthorne EA, Cheng Y, Lee E, Pure E, Assoian RK. (2007) Hyaluronan and CD44 antagonize mitogen-dependent cyclin D1 expression in mesenchymal cells. The Journal of Cell Biolog. 176:p.535–544.
74.Shai Y, Benarroch SA, Solans JM, Edelman ER. (2010) Monocyte activation state regulates monocyte-induced endothelial proliferation through Met signaling. Blood. 115:p.3407-3412.
75.Lechner MG, Liebertz DJ, Epstein AL. (2010) Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells. Journal of Immunology. 185:p.2273-2284.
76.Nicolini A, Carpi A, Rossi G. (2006) Cytokines in breast cancer. Cytokine & Growth Factor Reviews. 17:p.325–337.
77.Paterson RR. (2006) Ganoderma—a therapeutic fungal biofactory. Phytochemistry. 67:p.1985–2001.
78.Gao XX, Fei XF, Wang BX, Zhang J, Gong YJ, Minami M, Nagata T, Ikejima T. (2000) Effects of polysaccharides (FI0-b) from mycelium of Ganoderma tsugae on proinflammatory cytokine production by THP-1 cells and human PBMC (I). Acta pharmacologica Sinica. 21:p.1179–1185.
79.Gao XX, Wang BX, Fei XF, Zhang J, Gong YJ, Minami, M,Nagata T, Ikejima T. (2000) Effects of polysaccharides (FI0-c) from mycelium of Ganoderma tsugae on proinflammatory cytokine production by THP-1 cells and human PBMC (II). Acta pharmacologica Sinica. 21:p.1186–1192.
80.Kim YS, Eo K, Oh KW, Lee C, Han SS. (2000) Antiherpeticactivities of acidic protein bound polysaccharide isolated fromGanoderma lucidum alone and in combinations with interferons. Journal of ethnopharmacology. 72:p.451–458.
81.Kleinwachter P, Anh N, Kiet TT, Schlegel B, Dahse HM, Hartl A, Grafe U. (2001) Colossolactones, new triterpenoid metabolites from a Vietnamese mushroom Ganoderma colossum. Journal of natural products. 64:p.236–239.
82.Ukai S, Kiho T, Hara C, Kuruma I, Tanaka Y. (1983) Polysaccharides in fungi. XIV. Anti-inflammatory effect of the polysaccharides from the fruit bodies of several fungi. Journal of pharmacobio-dynamics. 6:p.983–990.
83.Zhu M, Chang Q, Wong LK, Chong FS, Li RC. (1999) Triterpene antioxidants from Ganoderma lucidum. Phytotherapy research. 13:p. 529–531.
84.Hu H, Ahn NS, Yang X, Lee YS, Kang KS. (2002) Ganoderma Lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. International journal of cancer. 102:p.250–253.
85.Liao CH, Hsiao YM, Lin CH, Yeh CS, Wang JC, Ni CH, Hsu CP, Ko JL. (2008) Induction of premature senescence in human lung cancer by fungal immunomodulatory protein from Ganoderma tsugae. Food and Chemical Toxicology. 46:p.1851–1859.
86.Hsieh CW, Lan JL, Meng Q, Cheng YW, Huang HM, Tsai JJ. (2007) Eosinophil Apoptosis Induced by Fungal Immunomodulatory Peptide-fve via Reducing IL-5a Receptor. Journal of the Formosan Medical Association. 106:p.36-43.
87.Liao CH, Hsiao YM, Hsu CP, Lin MY, Wang JC, Huang YL, Ko JL. (2006) Transcriptionally mediated inhibition of telomerase of fungal immunomodulatory protein from Ganoderma tsugae in A549 human lung adenocarcinoma cell line. Molecular carcinogenesis. 45:p.220–229.
88.Chakraborty S, Ghosh U, Bhattacharyya NP, Bhattacharya RK, Roy M. (2006) Inhibition of telomerase activity and induction of apoptosis by curcumin in K-562 cells. Mutation Research. 596:p.81-90.
89.Ramachandran C, Fonseca HB, Jhabvala P, Escalon EA, Melnick SJ. (2002) Curcumin inhibits telomerase activity through human telomerase reverse transcriptase in MCF-7 breast cancer cell line. Cancer Letters. 184:p.1–6.
90.Tsuruta F, Sunayama J, Mori Y, Hattori S, Shimizu S, Tsujimoto Y, Yoshioka K, Masuyama N, Gotoh Y. (2004) JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3proteins. The EMBO Journal. 23:p.1889–1899.
91.Jeurink PV, Noguera CL, Savelkoul HF, Wichers HJ. (2008) Immunomodulatory capacity of fungal proteins on the cytokine production of human peripheral blood mononuclear cells. International Immunopharmacology. 8:p.1124–1133.
92.Lin JY, Chen ML, Lin BF. (2006) Ganoderma tsugae in vivo modulates Th1/Th2 and macrophage responses in an allergic murine model. Food and Chemical Toxicolog. 44:p.2025–2032.
93.Wang PH, Hsu CI, Tang SC, Huang YL, Lin JY, Ko JL. (2004) Fungal Immunomodulatory Protein from Flammulina velutipes Induces Interferon-ç Production through p38 Mitogen-Activated Protein Kinase Signaling Pathway. Journal of Agricural and Food Chemistry. 52:p.2721-2725.
94.Rincon M, Enslen H, Raingeaud J, Recht M, Zapton T, Su MS, Penix LA, Davis RJ, Flavell RA. (1998) Interferongamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. The EMBO journal. 17:p.2817-2829.